Lesser-known facts about esophageal cancer

Share This Post

April 2023: April month is observed as esophageal cancer awareness month. Esophageal cancer is a type of cancer that affects the esophagus, the muscular tube that connects the throat to the stomach. Here are some lesser-known facts about esophageal cancer:

  1. It can be difficult to diagnose early: Esophageal cancer often does not cause symptoms until it has spread to other parts of the body. This can make it difficult to detect in its early stages.

It is often linked to lifestyle factors: Certain lifestyle factors can increase the risk of developing esophageal cancer, including smoking, heavy alcohol use, and obesity.

Gastroesophageal reflux disease (GERD) can increase the risk: GERD, a condition in which stomach acid backs up into the esophagus, can increase the risk of developing esophageal cancer, particularly adenocarcinoma.

There are two main types: Esophageal cancer can be classified as either adenocarcinoma or squamous cell carcinoma. Adenocarcinoma is more common in the United States, while squamous cell carcinoma is more common in other parts of the world.

Treatment options depend on the stage of the cancer: Treatment for esophageal cancer may include surgery, radiation therapy, chemotherapy, or a combination of these. The specific treatment options depend on the stage of the cancer and other factors, such as the patient’s overall health.

  1. Survival rates vary widely: The five-year survival rate for esophageal cancer is around 20%. However, this can vary widely depending on the stage of the cancer at diagnosis and other factors.
  1. It is more common in men: Esophageal cancer is more common in men than women, and the risk increases with age.
  2. There may be a genetic component: Some cases of esophageal cancer may have a genetic component, and individuals with a family history of the disease may be at increased risk.
  3. It can be prevented: Lifestyle changes, such as quitting smoking, limiting alcohol intake, and maintaining a healthy weight, can help reduce the risk of developing esophageal cancer.
  4. It can be detected through screening: Individuals with a higher risk of developing esophageal cancer, such as those with a history of GERD, may benefit from regular screening to detect the disease in its early stages.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy